bioAffinity Technologies, Inc. (BIAFW) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

bioAffinity Technologies filed an 8-K on May 8, 2026 to announce Q1 2026 financial results, indicating the company is maintaining regular reporting cadence as a Nasdaq-listed emerging growth company.
The filing contains minimal substantive detail, with the actual financial results and management commentary relegated to an attached press release (Exhibit 99.1), which is explicitly stated as non-filed and not incorporated by reference into SEC filings.
As an emerging growth company, bioAffinity has elected to use reduced regulatory requirements, though the company has not opted for the extended transition period for accounting standards compliance, suggesting a more conservative compliance posture.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-30

Stockholders approved a significant 15x increase in the equity incentive plan from 66,666 to 1,000,000 shares, indicating the company's plans for substantial employee compensation and potential dilution of existing shareholders.
Multiple warrant and preferred stock anti-dilution adjustments were approved, allowing up to 365,620 additional warrant shares and 131,884 preferred conversion shares, suggesting the stock price has declined below previous pricing levels.
The company secured shareholder authorization for non-public offerings and potential change of control transactions under Nasdaq Rule 5635(d), providing management significant flexibility for future capital raises but creating uncertainty for current shareholders.
All six director nominees were re-elected with strong support (>94% approval), and the company retained WithumSmith+Brown as auditors, indicating stable governance and no major internal conflicts.

Filed: 2026-04-14

bioAffinity Technologies announced the release of a new clinical case study for its CyPath® Lung diagnostic test, which helped determine next steps for a patient with a suspicious pulmonary nodule where imaging and risk models suggested a high likelihood of cancer, but the physician suspected possible inflammation.
The case study illustrates the potential value of CyPath® Lung in providing additional insights to help guide clinical decision-making for patients with pulmonary nodules, where standard imaging and risk assessment tools may not provide a definitive diagnosis.
As an emerging growth company, the release of this positive case study could help build momentum and awareness for bioAffinity's CyPath® Lung product among healthcare providers.

Filed: 2026-04-07

bioAffinity Technologies, Inc. announced that its CyPath® Lung test will be featured at a prestigious symposium on advances in early lung cancer detection, indicating potential progress in the company's diagnostic products.
The company is listed on the Nasdaq Capital Market, suggesting it has met the exchange's listing requirements and provides investors with greater access and liquidity.
As an emerging growth company, bioAffinity Technologies may have additional regulatory flexibilities and could be an interesting opportunity for investors seeking exposure to innovative healthcare technologies.

Filed: 2026-04-01

bioAffinity Technologies reported accelerating adoption of its CyPath® Lung diagnostic, with 146% year-over-year growth in unit sales during Q1 2026, exceeding internal projections.
The company's noninvasive lung cancer test is gaining traction with physicians and expanding in clinical use, which could drive further revenue growth.
As an emerging growth company, bioAffinity's financial results and operational performance will be closely watched by investors seeking signs of commercial viability.

Filed: 2026-03-26

bioAffinity Technologies, Inc. filed an 8-K report on March 26, 2026, providing an update on the company's operations and performance.
The company posted presentation materials to its website, indicating that management plans to use these materials in future presentations about the company.
As an emerging growth company, bioAffinity Technologies may have the option to take advantage of extended transition periods for complying with new or revised financial accounting standards.

Filed: 2026-03-25

bioAffinity Technologies, Inc. is hosting a virtual physician roundtable to discuss the use of their CyPath® Lung product in clinical practice for lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors.
The company's common stock and warrants are traded on the Nasdaq Capital Market, indicating it is an emerging growth company.
The filing does not mention any material agreements, leadership changes, or earnings surprises, suggesting this is a routine event update.

Filed: 2026-03-17

bioAffinity Technologies has released a new clinical case study highlighting the benefits of its noninvasive lung cancer test, CyPath Lung, for high-risk patients with multiple pulmonary nodules.
The company's stock trades on the Nasdaq Capital Market under the ticker symbols BIAF (common stock) and BIAFW (warrants).
bioAffinity Technologies is an emerging growth company, indicating potential for further development and growth opportunities.

Filed: 2026-03-10

bioAffinity Technologies has initiated a large-scale clinical study for its CyPath® Lung diagnostic test, which could potentially lead to increased adoption and revenue growth for the company's early-stage lung cancer detection product.
The company's common stock and warrants are now trading on the Nasdaq Capital Market, which could provide increased visibility and access to capital markets.
As an emerging growth company, bioAffinity Technologies may benefit from certain regulatory and financial reporting exemptions, but investors should be aware of the associated risks.

Filed: 2026-03-06

Two directors, Robert Anderson and Roby Joyce, have decided not to stand for re-election to the company's board at the upcoming annual meeting.
The departures do not appear to be due to any disagreements with the company, suggesting an amicable transition.
The company is an emerging growth company, indicating it may be in an earlier stage of development.

Filed: 2026-03-03

bioAffinity Technologies presented a poster at the AAAAI 2026 annual meeting, showcasing its development of clinical diagnostics that may assist physicians in matching asthma and COPD patients with effective therapies and improve healthcare outcomes.
The company's technology aims to monitor inflammatory changes over time, which could potentially lower the cost of healthcare for asthma and COPD patients.
As an emerging growth company, bioAffinity Technologies may have the opportunity to benefit from the extended transition period for complying with new or revised financial accounting standards.

Filed: 2026-02-25

bioAffinity Technologies announced a new study with Brooke Army Medical Center to validate the clinical utility of their CyPath® Lung diagnostic test for early lung cancer detection, which could expand the potential market for this product.
The company's common stock and warrants are traded on the Nasdaq Capital Market, indicating it has met the listing requirements and could have increased visibility and access to capital markets.
As an emerging growth company, bioAffinity may have flexibility in complying with certain financial reporting and accounting standards, which could impact how investors evaluate the company.

Filed: 2026-02-19

bioAffinity Technologies, Inc. released a new clinical case study demonstrating how their CyPath® Lung product can help determine appropriate treatment for patients with suspicious lung findings.
The company's CyPath® Lung product appears to be gaining traction and demonstrating clinical value, which could indicate potential growth opportunities.
As an emerging growth company, bioAffinity Technologies is subject to certain financial reporting and disclosure requirements, which investors should monitor closely.

Filed: 2026-02-17

bioAffinity Technologies announced the release of a new clinical case study demonstrating how their CyPath® Lung product supported clinical decision making for a high-risk patient with multiple pulmonary nodules.
This press release highlights the potential clinical utility of bioAffinity's diagnostic technology, which could be a positive development for the company's product pipeline and commercial prospects.
As an emerging growth company, this announcement may be indicative of bioAffinity's efforts to demonstrate the value of its technology and drive further adoption in the market.

Filed: 2026-02-10

bioAffinity Technologies, Inc. has filed an 8-K report, indicating a potential material event or update for investors to consider.
The company has posted new presentation materials on its website, which may provide insights into its operations and performance.
As an emerging growth company, bioAffinity Technologies may have flexibility in financial reporting standards and disclosure requirements.

Filed: 2026-02-09

bioAffinity Technologies, Inc. has expanded its Medical and Scientific Advisory Board with the appointments of David Ost, MD, MPH, Daniel Sterman, MD, and J. Scott Ferguson, MD, which may enhance the company's medical expertise and bolster investor confidence.
The additions to the advisory board could provide valuable guidance on the company's product development and clinical strategies, potentially accelerating the commercialization of its technologies.
The press release suggests the company is actively strengthening its medical and scientific capabilities, which could be seen as a positive signal for investors.

Filed: 2026-02-04

The company has scheduled its 2026 Annual Meeting of Stockholders for April 30, 2026, which will include proposals from the previously adjourned Special Meeting.
Shareholders seeking to bring business or nominate directors must provide written notice by February 14, 2026, in accordance with the company's bylaws.
The company's common stock and warrants to purchase common stock are traded on the Nasdaq Capital Market.

Filed: 2026-01-07

bioAffinity Technologies' wholly owned subsidiary, Precision Pathology Laboratory Services, has successfully maintained its accreditation from the College of American Pathologists, indicating the company's commitment to quality standards and processes.
The company's common stock and warrants continue to trade on the Nasdaq Capital Market, providing investors with access to the publicly traded securities.
As an emerging growth company, bioAffinity Technologies may elect to use the extended transition period for complying with new or revised financial accounting standards, which could impact future financial reporting.

Other reports for bioAffinity Technologies, Inc.

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.